August 12, 2024
“CervoMed (CRVO) The first Morgan Stanley pick we’ll look at is CervoMed, a clinical-stage medical research firm specializing in neurodegenerative diseases and conditions… Overall, the analyst expects positive clinical results and rates CRVO an Overweight (i.e., Buy). His $35 price… Continue Reading…
March 29, 2024
“Viking Therapeutics shares closed more than 15% higher on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year… Viking is one of several small… Continue Reading…
February 29, 2024
“Shares of Viking Therapeutics closed more than 120% higher on Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say… Continue Reading…
Recent Comments